{"symbol": "207940.KS", "name": "Samsung Biologics Co.,Ltd.", "description": "Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.", "sector": "Healthcare", "industry": "Biotechnology", "employees": 4770, "website": "https://samsungbiologics.com", "city": "Incheon", "country": "South Korea", "currency": "KRW", "marketCap": 90128479420416, "trailingPE": null, "forwardPE": 48.34058, "trailingEps": null, "dividendYield": null, "dividendRate": null, "priceToBook": null, "profitMargins": 0.28991, "beta": 0.19, "fiftyTwoWeekHigh": 1987000.0, "fiftyTwoWeekLow": 1509860.2, "averageVolume": 53887, "totalRevenue": 5504838402048, "grossProfits": 3077817761792, "totalCash": 1960050032640, "totalDebt": 1221620006912, "ebitda": 2688135200768, "lastUpdated": "2026-01-18T13:31:58.353006Z"}